Is Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), -73.06% away from high, Poised For A Strong …

In last trading session, Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) saw 441,638 shares changing hands with its beta currently measuring 1.48. Company’s recent per share price level of $25.17 trading at $0.3 or 1.21% at ring of the bell on the day assigns it a market valuation of $2.02 Billion. That closing price of ITCI’s stock is at a discount of -73.06% from its 52-week high price of $43.56 and is indicating a premium of 60.99% from its 52-week low price of $9.82. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 906.68 Million shares which gives us an average trading volume of 1.96 Million if we extend that period to 3-months.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

For Intra-Cellular Therapies, Inc. (ITCI), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.5. Splitting up the data highlights that, out of 9 analysts covering the stock, none rated the stock as a Sell while none recommended an Overweight rating for the stock. None suggested the stock as a Hold whereas 9 see the stock as a Buy. None analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.86 in the current quarter.

Upright in the green today for gaining 1.21%, in the last five days ITCI remained trading in the green while hitting it’s week-highest on Friday, Dec 04 when the stock touched $25.46- price level, adding 1.14% to its value on the day. Intra-Cellular Therapies, Inc.’s shares saw a change of -26.64% in year-to-date performance and have moved 0.76% in past 5-day. Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) showed a performance of -4.91% in past 30-days. Number of shares sold short was 5.77 Million shares which calculate 2.94 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of $48.11 to the stock, which implies a rise of 91.14% to its current value. Analysts have been projecting $36 as a low price target for the stock while placing it at a high target of $80. It follows that stock’s current price would jump +217.84% in reaching the projected high whereas dropping to the targeted low would mean a loss of 43.03% for stock’s current value.

Intra-Cellular Therapies, Inc. (ITCI) estimates and forecasts

Statistics highlight that Intra-Cellular Therapies, Inc. is scoring comparatively higher than the scores of other players of the relevant industry. The company added +12.52% of value to its shares in past 6 months, showing an annual growth rate of 22.01% while that of industry is 14.1. Apart from that, the company came lowering its revenue forecast for fiscal year 2020. The company is estimating its revenue growth to decline by -16.2% in the current quarter and calculating -19.2% decline in the next quarter. This year revenue growth is estimated to rise 38333.3% from the last financial year’s standing.

10 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $12.82 Million for the same. And 3 analysts are in estimates of company making revenue of $18.3 Million in the next quarter that will end in March 01, 2021. Company posted $60Million and $1.08 Million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to grow by 21266.7% while estimating it to be 1589.8% for the next quarter.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -20.1% during past 5 years. In 2020, company’s earnings growth rate is likely to be around 5.6% while estimates for its earnings growth in next 5 years are of 0%

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)’s Major holders

Insiders are in possession of 4.99% of company’s total shares while institution are holding 86.05% percent of that, with stock having share float percentage of 90.57%. Investors also watch the number of corporate investors in a company very closely, which is 252 institutions for Intra-Cellular Therapies, Inc. that are currently holding shares of the company. FMR, LLC is the top institutional holder at ITCI for having 11.84 Million shares of worth $303.75 Million. And as of September 29, 2020, it was holding 14.77% of the company’s outstanding shares.

The second largest institutional holder is Vanguard Group, Inc. (The), which was holding about 6.23 Million shares on September 29, 2020. The number of shares represents firm’s hold over 7.77% of outstanding shares, having a total worth of $159.84 Million.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

On the other hand, Fidelity Growth Company Fund and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of September 29, 2020, the former fund manager was holding 3739951 shares of worth $95.97 Million or 4.67% of the total outstanding shares. The later fund manager was in possession of 2.01 Million shares on September 29, 2020, making its stake of worth around $51.49 Million in the company or a holder of 2.5% of company’s stock.

My #1 Stock Trade This Year (HINT: It’s a COVID-19 Play)

Get Ready for my next COVID-19 stock idea.
I have been very fortunate in discovering biotech, therapeutic and diagnostic companies within the COVID-19 space, before wall street catches on. Our goal for our members is to get our Alert’s first before the crowd.

>> Sign Up Now to Get Name & Ticker Symbol of Next Triple-Digit Gainer


Latest posts